faropenem faropenem faropenem is an orally active beta-lactam antibiotic belonging to the penem group. it is resistant to some forms of extended-spectrum beta-lactamase. it is available for oral use. faropenemclinical dataahfs/drugs.cominternational drug namesroutes ofadministrationoralatc codej01di03 (who) identifierscas number106560-14-9 npubchem cid65894chemspider59303 yuniif52y83bgh3chebichebi:51257 ychemblchembl556262 ycomptox dashboard (epa)dtxsid0046430 chemical and physical dataformulac12h15no5smolar mass285.31 g·mol−13d model (jsmol)interactive image smiles o=c2n1/c(=c(\s12(o)c)3occc3)c(=o)o inchi inchi=1s/c12h15no5s/c1-5(14)7-10(15)13-8(12(16)17)9(19-11(7)13)6-3-2-4-18-6/h5-7,11,14h,2-4h2,1h3,(h,16,17)/t5-,6-,7+,11-/m1/s1 ykey:hggakxahayoldj-fhzuqptbsa-n y ny (what is this?) (verify) forms faropenem was developed by daiichi asubio pharma, which markets it in two forms. the sodium salt faropenem sodium, available under the trade name farom, has been marketed in japan since 1997. (cid 636379 from pubchem) the prodrug form faropenem medoxomil (also known as faropenem daloxate) has been licensed from daiichi asubio pharma by replidyne, which plans to market it in conjunction with forest pharmaceuticals. the trade name proposed for the product was orapem, but company officials recently announced this name was rejected by the fda. clinical use as of 8 september 2015, faropenem has yet to receive marketing approval in the united states, and was submitted for consideration by the united states food and drug administration (fda) on 20 december 2005. the new drug application dossier submitted included these proposed indications: acute bacterial sinusitis community-acquired pneumonia acute exacerbations of chronic bronchitis uncomplicated skin and skin structure infections urinary tract infections history the fda refused to approve faropenem, an antibiotic manufactured by louisville-based replidyne. the fda said the drug was “nonapprovable”, but did not refer to specific safety concerns about the product. the company will have to conduct new studies and clinical trials, lasting an estimated two more years, to prove the drug treats community-acquired pneumonia, bacterial sinusitis, chronic bronchitis, and skin infections. in india it is available as farobact 200/300er cipla.